èšåºæ®µéã®ãã€ãªå»è¬åäŒæ¥ã§ãã Fate Therapeutics, Inc. ã¯ãäžçäžã®ããããã³å
ç«çŸæ£ã«å¯Ÿããããã°ã©ã 现èå
ç«çæ³ãéçºããŠããŸããéçºäžã® NK 现èããã³ T 现èå
ç«è
«çããã°ã©ã ã«ã¯ãæ¥æ§éªšé«æ§çœè¡ç
(AML)ãB 现èãªã³ãè
«ãé²è¡æ§åºåœ¢è
«çã®æ²»çãç®çãšãã FT516ãB 现èãªã³ãè
«ããã³æ
¢æ§ãªã³ãæ§çœè¡ç
ãæ²»çããããã® FT596ãAML ããã³å€çºæ§éªšé«è
«ãæ²»çããããã® FT538ãå€çºæ§éªšé«è
«ãæ²»çããããã® FT576ãè¡æ¶²æªæ§è
«çããã³åºåœ¢è
«çãæ²»çããããã® FT819ãåºåœ¢è
«çãæ²»çããããã® FT536ãé²è¡æ§åºåœ¢è
«çãæ²»çããããã® FT500ãããã³è¡æ¶²æªæ§è
«çããã³åžå°éºäŒæ§çŸæ£ãæ²»çããããã® ProTmune ããããŸããå瀟ã¯ãåžè²©ã®iPSCç±æ¥CAR T现è補ååè£2çš®ã®éçºãšåååã«ã€ããŠå°éè¬åå·¥æ¥æ ªåŒäŒç€Ÿãšææºããã³ãªãã·ã§ã³å¥çŽãç· çµããŠããã»ããéºäŒåçµã¿æãT现èå
ç«çæ³ã®æ²»çç¹æ§ãé«ããå°ååã¢ãžã¥ã¬ãŒã¿ãŒã®ã¹ã¯ãªãŒãã³ã°ãšç¹å®ã«ã€ããŠJuno Therapeutics, Inc.ãšæŠç¥çç ç©¶ææºããã³ã©ã€ã»ã³ã¹å¥çŽãç· çµããŠããã»ããJanssen Biotech, Inc.ãšææºããã³ãªãã·ã§ã³å¥çŽãç· çµããŠãããFate Therapeutics, Inc.ã¯2007幎ã«èšç«ãããã«ãªãã©ã«ãã¢å·ãµã³ãã£ãšãŽã«æ¬ç€Ÿã眮ããŠããã